Istgtkd5awwacqssgxfa

AstraZeneca expands 1st-line lung cancer immuno-oncology programme opportunities

Pressmeddelanden   •   Jan 17, 2017 08:07 CET

Refined endpoints and statistical analysis plan in the Phase III MYSTIC trial China regulatory submission opportunity strengthened with the expansion of the Phase III NEPTUNE trial and the initiation of the new Asia-focused Phase III PEARL trial

Istgtkd5awwacqssgxfa

US FDA accepts first biologics license application for AstraZeneca’s durvalumab in bladder cancer

Pressmeddelanden   •   Dec 09, 2016 16:10 CET

​FDA grants priority review status with PDUFA set for Q2 2017

Istgtkd5awwacqssgxfa
Hdv81iuwcb3hfqynjijv

Tagrisso (osimertinib) visar på förbättrade resultat vid EGFR T790M icke småcellig lungcancer jämfört med cytostatika

Pressmeddelanden   •   Dec 06, 2016 10:32 CET

Den första randomiserade fas 3-studien (AURA3) som jämför osimertinib med dubbel platinumbaserad cytostatikabehandling Osimertinib förbättrade progressionsfri överlevnad med nästan sex månader Patienter med metastaser på centrala nervsystemet visade på liknande resultat som den totala populationen enligt förbestämda subgruppsanalyser

Istgtkd5awwacqssgxfa

AstraZeneca takes latest scientific advances in oncology to major US and European congresses

Pressmeddelanden   •   Nov 29, 2016 08:03 CET

​Tagrisso scientific updates include results of AURA3 trial in patients with lung cancer, and Phase II efficacy data on CNS metastases New analyses of Phase III FALCON trial will extend understanding of Faslodex in 1st-line treatment of advanced breast cancer New acalabrutinib safety and efficacy data in patients with difficult-to-treat chronic lymphocytic leukaemia

Istgtkd5awwacqssgxfa

AstraZeneca head and neck cancer trials resume new patient enrolment as FDA lifts partial clinical hold

Pressmeddelanden   •   Nov 22, 2016 08:15 CET

AstraZeneca today announced that the US FDA has lifted the partial clinical hold on the enrolment of new patients with head and neck squamous cell carcinoma (HNSCC) for clinical trials of durvalumab as monotherapy and in combination with tremelimumab or other potential medicines.

Ft3pxhsas3w6udxlrbmr
Hdv81iuwcb3hfqynjijv

AstraZeneca uppmärksammar Världsdiabetesdagen den 14 november

Nyheter   •   Nov 14, 2016 16:47 CET

Korta fakta om diabetes - en växande folksjukdom. AstraZeneca har som mål att förbättra livet för personer med diabetes genom att minska påverkan av sjukdomen och dess komplikationer. Vi forskar inom metabola sjukdomar och har en ambition att vara ledande på området. AstraZeneca erbjuder olika behandlingsmöjligheter inom typ 2-diabetes.

Istgtkd5awwacqssgxfa

AstraZeneca PLC:s resultatrapport för de första nio månaderna och tredje kvartalet 2016

Pressmeddelanden   •   Nov 10, 2016 08:18 CET

​Resultatet för tredje kvartalet är i linje med våra förväntningar

Istgtkd5awwacqssgxfa

Lynparza Phase III SOLO-2 trial shows significant progression-free survival benefit

Pressmeddelanden   •   Okt 26, 2016 08:02 CEST

Trial studied Lynparza as maintenance treatment for women with BRCA-mutated metastatic ovarian cancer Initial findings show safety profile with Lynparza tablets was consistent with previous studies

Media no image

FDA accepts for review New Drug Application for sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalaemia

Pressmeddelanden   •   Okt 18, 2016 08:03 CEST

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a complete re-submission of a New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), a potential new medicine for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca. The FDA has indicated that this is a complete class 2 response.

Interactions with other health authorities in the European Union and Australia are ongoing with decisions expected in the first half of 2017.

– ENDS –

NOTES TO EDITORS

About sodium zirconium cyclosilicate (ZS-9) for oral suspension

Sodium zirconium cyclosilicate (ZS-9) is an insoluble, non-absorbed compound with a structure that was designed to preferentially capture potassium ions. Sodium zirconium cyclosilicate has been studied in three double-blind, placebo controlled trials and in one ongoing 12-month open label clinical trial in patients with hyperkalaemia which represents over 1,600 patients treated. Sodium zirconium cyclosilicate is an investigational medicine that is not currently approved for any indication in any market.

About hyperkalaemia

Hyperkalaemia (potassium levels > 5.0 mEq/L in the blood serum) commonly occurs in patients with advanced chronic kidney disease and/or chronic heart failure, and may lead to cardiac arrest and death. Treatment with common heart medicines (RAAS inhibitors) can also be responsible for increases in hyperkalaemia. Current therapeutic options are limited, leaving a high unmet medical need in these patients.

About ZS Pharma ZS Pharma was founded in 2008, became a public company in 2014 and, in December 2015, joined the AstraZeneca Group. ZS Pharma is focused on the development and commercialisation of highly selective, non-absorbed drugs to treat renal, cardiovascular and metabolic disorders. Additional information about ZS Pharma is available at www.zspharma.com.

About AstraZeneca in Cardiovascular & Metabolic Disease (CVMD)

Cardiovascular, metabolic disease and chronic kidney disease are key areas of focus for AstraZeneca as part of the company’s strategy for achieving scientific leadership and returning to growth. Our patient-led strategy is focused on addressing the multiple risk factors facing CVMD and CKD patients at different stages of their disease, with the goal of reducing morbidity and mortality through life changing medicines.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.comand follow us on Twitter @AstraZeneca.

CONTACTS

Media Enquiries
Neil Burrows UK/Global +44 203 749 5637
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, neuroscience & infection +44 203 749 5711
US toll free +1 866 381 7277

Om AstraZeneca

AstraZeneca är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom tre terapiområden - andningsvägar, hjärta/kärl/metabolism och cancer men är också selektivt aktiv inom områdenaneurovetenskap och autoimmunitet. AstraZeneca är verksamt i över 100 länder och våra innovativa läkemedel används av miljontals patienter världen över. Mer information finns på: www.astrazeneca.com och www.astrazeneca.se

Läs vidare »
Media no image

AstraZeneca enters agreement with Cilag GmbH International to divest rights to Rhinocort Aqua outside the US

Pressmeddelanden   •   Okt 07, 2016 08:04 CEST

AstraZeneca today announced that it has entered into an agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the US.

Rhinocort Aqua is a nasal spray indicated for allergic and non-allergic rhinitis(inflammation of the inside of the nose), and for the treatment of nasal polyps (swelling of the nasal lining). The active ingredient is the anti-inflammatory medicine budesonide.

Mark Mallon, Executive Vice President, Global Product & Portfolio Strategy at AstraZeneca, said: “This agreement allows us to concentrate our efforts in Respiratory as one of our three strategic therapy areas, on transforming the treatment of asthma and COPD, where budesonide remains a key component of our marketed as well as pipeline medicines.”

Financial considerations

The agreement is subject to customary closing conditions and is expected to complete in the fourth quarter of 2016. As AstraZeneca will not maintain a significant ongoing interest in Rhinocort Aqua, the $330 million payment received from Cilag GmbH International upon completion of the transaction will be recognised as Other Operating Income in the Company’s financial statements. The transaction does not include the transfer of any AstraZeneca employees or facilities and does not impact the Company’s financial guidance for 2016.

-ENDS-

NOTES TO EDITORS

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory, Cardiovascular & Metabolic Diseases, and Oncology. The Company is also selectively active in Neuroscience and Autoimmunity. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Neil Burrows UK/Global +44 203 749 5637
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
UK
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Nick Stone Respiratory +44 203 749 5716
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris Neuroscience & Autoimmunity +44 203 749 5711
US
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Mitchell Chan Oncology +1 240 477 3771
Toll-free +1 866 381 7277

Om AstraZeneca

AstraZeneca är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom tre terapiområden - andningsvägar, hjärta/kärl/metabolism och cancer men är också selektivt aktiv inom områdena neurovetenskap och autoimmunitet. AstraZeneca är verksamt i över 100 länder och våra innovativa läkemedel används av miljontals patienter världen över. Mer information finns på: www.astrazeneca.com och www.astrazeneca.se

AstraZeneca today announced that it has entered into an agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the US.

Läs vidare »

Kommande evenemang 1 evenemang

02 Feb 09:00

Inbjudan till presskonferens - AstraZenecas resultatrapport fjärde kvartalet och helåret 2016

2017-02-02, 09:00 - 10:15
Goldman Sachs, River Court, 7th Floor, 120 Fleet Street, London, EC4A 2BE

Kontaktpersoner 3 kontaktpersoner

  • Presskontakt
  • Extern kommunikationsdirektör
  • hrjacob.lundwdegdrcz@astpwlvrarnrbayyjzesshwneihcaaykw.com
  • 08 553 260 20 Mobil: 072 560 21 57

Om AstraZeneca

Om AstraZeneca

AstraZeneca är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom tre terapiområden - andningsvägar, hjärta/kärl/metabolism och cancer men är också selektivt aktiv inom områdena autoimmunitet, neurovetenskap och infektion. AstraZeneca är verksamt i över 100 länder och våra innovativa läkemedel används av miljontals patienter världen över. Mer information finns på: www.astrazeneca.com och www.astrazeneca.se